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Purpose: To determine the associations between glycated hemoglobin (A1C)
values at three, 12 and 24 months postpartum taken during the Families
Defeating Diabetes trial.
Methods: The Families Defeating Diabetes trial was a randomized 12 month
lifestyle intervention delivered in the first year postpartum. Women were
reviewed at three, 6 12 and 24 months for body habitus, diet and lifestyle
choices. Glycated hemoglobin levels were measured at three, 12 and 24 months.
Results: There were 170 randomization participants: 89 interventional (INT);
and 81 control (CON). Of these 170 participants, 50 INT and 47 CON
completed 12-month follow-up and 26 INT and 24 CON completed 24-month
follow-up. Study outcomes did not differ between the cohorts. Combined
intraclass correlation coefficients for reliability of repeated results showed
substantial reliability: 0.74 (95% CI 0.63, 0.83) between three and 12 month
A1C; and 0.72 (95% CI 0.51, 0.85) for three and 24 month A1C. Pearson
correlations for three month vs 12 month A1C were r=0.745 (p<0.001) and
three month vs 24 month A1C were r=0.718 (p=0.001)
Conclusions: The A1C values at three, 12 and 24 months after gestational
diabetes mellitus showed substantial reliability by intraclass correlation
coefficients analysis as well as significant Pearson correlations. These findings
add perspective to timing and use of A1C to document postpartum glucose
tolerance for women with recent gestational diabetes mellitus. These findings
suggest a role for postpartum A1C testing; however, a longitudinal comparison
with OGTT results is required to confirm clinical validity.
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Women with gestational diabetes mellitus (GDM) are at
significantly increased risk not only for recurrent GDM and
metabolic syndrome [1] but for developing type 2 diabetes
[2,3]; therefore, postpartum glucose tolerance assessment is
strongly recommended [4,5]. Despite much effort, achieving
more than a 50% completion rate for postpartum oral
glucose tolerance testing (OGTT) has been challenging [6,7].
The use of glycated hemoglobin (A1C) levels as an
alternative to OGTT for diagnosing prediabetes and diabetes
has associated convenience, but has also generated
controversy in GDM follow-up (8,9) as well as in defining
which A1C value is reliably associated with impaired glucose
tolerance and/or impaired fasting glucose within wider
populations [10,11]. Despite these debates, clinical practice
guidelines, including those from the American Diabetes
Association and Diabetes Canada, identify the A1C as a
screening tool with utility for both diabetes and prediabetes
in non-pregnant and postpartum settings [12,13]. Therefore,
it was of interest whether successive A1C values taken after
GDM would show any reliable relationship over time.
Families Defeating Diabetes (FDD) was a 12 month
Canadian randomized controlled trial of a postpartum
healthy living intervention for women with recent GDM,
and included a 24 month final study contact [14]. Although
the FDD intervention was not associated with significant
changes in the main outcomes of interest at 12 months
(body habitus, lifestyle choices or A1C measures between
interventional (INT) and control (CON)), blood samples for
A1C testing were collected at three, 12 and 24 months as
part of the study protocol.
Relationships between repeated lab measurements can
be expressed through analysis of intraclass correlations
(ICC), which indicate how strongly results within the same
group resemble each other, as well as by analysis of Pearson
correlations, which reflect the relatedness of results in each
pair of individuals [15,16]. Both ICCs and Pearson
correlations for the GDM study’s A1C values are presented
here with the aim to inform decisions of timing and options
for postpartum dysglycemia testing.

Methods
Participants
Methods and results were published previously [14]. In
summary, English-speaking, overweight women with GDM
were recruited during late pregnancy or early after delivery
from three Canadian sites: London, Ontario; Calgary,
Alberta; and Victoria, British Columbia. The study was
approved by the site Ethics Committee and registered at
Clinicaltrials.gov as NCTO1425645; Families Defeating
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Diabetes. After informed consent, women were randomized
to intervention (INT, N=89) or control group (CON,
N=81). The intervention was 12 months in duration, with
visits at three and 12 months, followed by a final contact at
24 months.
Measurements
Non-fasting blood samples for hemoglobin (A1C) were
taken from maternal participants at three, 12 and 24 months
for local analysis. The A1C test measures the amount of
hemoglobin with attached glucose, and reflects average
blood glucose levels over the previous three months.
Measurements are expressed as a percentage. Non-diabetic
range for A1C was <6.5% at all sites. The A1C measurement
was chosen over OGTT to assess study glucose tolerance for
pragmatic compliance reasons: 1) A1C was more convenient
than asking women to accept three iterations of OGTT
testing during the 24 months of study follow up; 2) A1C
could be measured at any time of day allowing combination
with other study tasks and participants were not restricted to
early morning appointments; and 3) prior reports had
discouragingly poor OGTT attendance rates despite active
encouragement [6,7,17,18].
Statistical analysis
Between-group comparisons for A1C levels were made using
unpaired t-tests and between group differences were
unadjusted. Intraclass correlation coefficients (ICC) are used
for evaluation of test-retest agreement. ICC point estimates
and 95% two-sided confidence intervals (CIs) were
determined using one-way analysis of variance (ANOVA)
models. Confidence intervals were obtained by using the
approximate F-distribution. Study results were interpreted
according to Landis and Koch (19) where ICCs of <0.2
indicate poor or slight agreement; 0.21-0.4 indicate fair
agreement; 0.41-0.6 indicate moderate agreement; 0.61-0.8
indicate substantial agreement; >0.8 indicate almost perfect
agreement. Furthermore, Pearson correlations were
calculated for A1C at three, 12 and 24 months. Associations
were sought between A1C and breastfeeding, maternal
weight, maternal waist circumference, weight loss and family
income. All statistics were calculated using SAS software and
significance was accepted at p ≤0.05.

Results
Of the 170 women who were recruited for the study, 97
completed 12 months of the study, and 75 of the 97 had
A1C results (INT N=39/50; CON N=36/47). Women were
predominantly Caucasian (71%). Results were excluded from
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the four women were pregnant at the 12 month visit (three
INT, one CON). Two INT women were using metformin
for fertility or menstrual issues, but without a diagnosis of
DM. Two CON women reported an intervening diagnosis
of DM, one of whom was on insulin and pregnant
(excluded, as noted above) and the other being the sole study
woman with an A1C >6.4% (7.2%). Equal numbers of INT
and CON women had undergone delivery by caesarian
section (seven women in each cohort). The A1C values did
not differ between INT and CON women at three, 12 or 24
months follow-up (Table 1). The A1C values at the 3-month
follow-up for women who dropped out of the study did not
differ significantly from that of women who completed the
12-month follow-up: 5.8±1.2% compared with 5.5±0.4%;
p=0.082. The ICCs were 0.74 (95% CI: 0.63, 0.83) for three
and 12 months and 0.72 (95% CI 0.51, 0.85) for three and 24
months (INT and CON cohorts combined).

TABLE 1. Glycated hemoglobin values measured
at three, 12 and 24 months
INT

CON

p-value

3 months

5.5±0.4%
N=89

5.4±0.5%
N=81

0.301

12 months

5.5±0.03%
N=39

5.5±0.5%
N=36

0.885

24 months

5.6±0.3%
N=16

5.3±0.5%
N=16

0.154

Abbreviation: CON, control; INT, interventional
Results presented as mean±SD.
Pearson correlations for A1C values at three and 12
months were significant: r=0.745, p<0.001 (INT and CON
cohorts combined). Furthermore, although numbers were
small, the 24 month A1C results remained significantly
correlated with both three and 12 month results (Table 2).
The A1C values were not associated with number of
months spent breastfeeding, maternal weight, maternal waist
circumference or weight loss. The A1C values were found to
be higher in women reporting a family history of diabetes at
12 months (positive family history: 5.6±0.5% compared with
negative family history: 5.4±0.3%, p=0.01) as well as 24
months (positive family history: 5.7±0.3% compared to
negative family history: 5.3±0.05%, p=0.04).
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Table 2. Pearson correlations for glycated
hemoglobin levels measured at three, 12, and 24
months
Cohort

3 months

12 months

Combined CON and INT cohorts
3 months

-

-

12 months

0.745*

-

24 months

0.718*

0.784*

-

-

12 months

0.817*

-

24 months

0.741**

0.789*

-

-

12 months

0.594*

-

24 months

0.703*

0.836*

CON cohort
3 months

INT cohort
3 months

Abbreviation: CON, control; INT, interventional
*p<0.001; ** p<0.002

Discussion
Glycated hemoglobin values at three, 12 and 24 months in
women with recent GDM were found to have substantial
reliability by ICC analysis, as well as exhibit significant
Pearson correlation. We concluded that A1C values were
significantly correlated at three, 12 and 24 months in women
with recent GDM, supporting a possible clinical role for
A1C in documenting postpartum glucose tolerance as early
as three months postpartum.
Current practice guidelines recommend that women with
GDM undergo a postpartum OGTT between 4/6 weeks and
six months [4,5]. Significant efforts have been made to
encourage postpartum OGTT testing with varying reminder
cues for patients and/or physicians, yet compliance rates are
rarely higher than 50% [6,7,17,18]. In addition to the
presumed underlying anxiety about having a test result in the
diabetes range, barriers to postpartum OGTT testing may
include the following: having to remain quiet for the 2-hour
lab test; fasting in a busy household; accessing early morning
child care; and caring for a small child in a lab waiting room
[20].
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Although the foregoing practical issues might be
ameliorated somewhat by using a random A1C testing versus
OGTT, there has been clinical discomfort with using A1C
testing after GDM due to potentially confounding issues,
including red cell turnover soon after delivery, as well as lack
of sensitivity compared with OGTT especially in defining
prediabetes states of impaired glucose tolerance or impaired
fasting glucose [21,22]. While the OGTT is the historical
postpartum gold standard, as a test it may not be highly
reproducible [23,24].
Although reassuring that A1C values as early as three
months showed significant correlations with the 12 and 24
month results, this finding may not be surprising as Pearson
correlation analyses compare each subject with herself over
time [15,16]. However, the ICC analysis revealed that A1C
levels were also in “substantial” reliability for both three and
12 months as well as three and 24 months. These results may
add some reassurance to decisions surrounding postpartum
glycemia test choice and timing as A1C results taken at the
three study intervals over two years were significantly related,
including samples taken as early as three months.
The study has acknowledged limitations. The A1C
results represent a post hoc analysis as FDD was not
designed nor powered to compare A1C testing with OGTT.
Participants rarely had A1C results that were out of normal
ranges so conclusions may not apply to a more glucose
intolerant population. Participants were predominantly
Caucasian without suspected hemoglobin abnormalities so
results may not apply to more diverse populations.
Furthermore, while results for the 14 women who had
undergone a caesarian section were included in the analyses,
estimated blood loss at delivery and concurrent hemoglobin
levels were not documented. Therefore, conclusions may not
apply to women with significant postpartum blood loss or
ongoing anemia.
The results for ICC reliability and Pearson correlations
between A1C values at three, 12 and 24 months would
support some utility in using A1C to assess glycemic balance
postpartum. Glycated hemoglobin is an accepted screening
tool for diagnosing dysglycemia in the general population
[12,13] and healthy women fully recovered from any
associated blood loss after a recent GDM pregnancy should
not differ from the background population deemed
appropriate for A1C screening. The principles used in
choosing A1C testing in this FDD study can also apply to
real world postpartum follow up as A1C testing eliminates
the maternal barriers associated with OGTT tests such as
preparatory carbohydrate loading, followed by fasting, and
then attending a two-hour lab test. While this report
illustrates the reliability of repeated A1C testing after GDM,
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confirmation of its clinical validity would depend upon a
further investigation wherein A1C testing and fasting OGTT
are performed longitudinally in a larger and more diverse
population.
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